INMD Stock Analysis: InMode | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 876m USD | 12M Return: 5% | IL0011595993 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.00M
EPS Trend: -96.4%
Qual. Beats: 0
Rev. Trend: -92.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
InMode Ltd. (NASDAQ: INMD) is an Israel-based medical device company incorporated in 2008 and headquartered in Yokneam, Israel, that designs, manufactures, and markets minimally invasive and non-invasive aesthetic medical products built around its proprietary radiofrequency (RF) technologies, including radiofrequency assisted lipolysis (RFAL) and deep subdermal fractional RF. The company serves a broad range of aesthetic and medical procedures spanning liposuction with skin tightening, body and face contouring, ablative skin rejuvenation, womens health applications, hair reduction, wrinkle reduction, cellulite treatment, and the treatment of superficial benign vascular and pigmented lesions, and has also expanded into hands-free platforms targeting skin tightening, fat reduction, and muscle stimulation.
The company sells its products through a distributor-based international model across more than a dozen markets, including the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxembourg, Italy, Germany, Austria, Japan, Australia, and India. Originally founded as Invasix Ltd., the company was renamed InMode Ltd. in November 2017 and completed its U.S. IPO in August 2019, listing on NASDAQ as a small-cap stock within the GICS Health Care Equipment sub-industry.
The medical aesthetics device sector in which InMode competes has historically been driven by rising consumer demand for non-surgical and minimally invasive cosmetic procedures, an ongoing shift away from invasive plastic surgery, and the broader adoption of energy-based devices (using RF, laser, or ultrasound) by dermatologists, plastic surgeons, and medical spas. InModes multi-platform portfolio, spanning physician-operated minimally invasive systems, non-invasive aesthetic products, and newer hands-free devices, allows it to address multiple price points and provider settings within this growing global market.
- US minimally invasive procedure demand drives revenue growth
- Competition from BTL and AbbVie pressures aesthetic device market share
- International expansion in Asia and Europe accelerates sales
- Consumer spending weakness pressures elective aesthetic procedure volumes
| Net Income: 77.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -2.57 > 1.0 |
| NWC/Revenue: 152.3% < 20% (prev 142.5%; Δ 9.80% < -1%) |
| CFO/TA 0.12 > 3% & CFO 88.6m > Net Income 77.5m |
| Net Debt (-496.7m) to EBITDA (84.2m): -5.90 < 3 |
| Current Ratio: 8.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.4m) vs 12m ago -6.69% < -2% |
| Gross Margin: 76.52% > 18% (prev 79.98%; Δ -3.46% > 0.5%) |
| Asset Turnover: 52.44% > 50% (prev 56.69%; Δ -4.25% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.79 (Total Current Assets 650.0m - Total Current Liabilities 79.4m) / Total Assets 720.3m |
| B: 1.34 (Retained Earnings 968.5m / Total Assets 720.3m) |
| C: 0.12 (EBIT TTM 83.5m / Avg Total Assets 714.3m) |
| D: 6.90 (Book Value of Equity 629.1m / Total Liabilities 91.2m) |
| Altman-Z'' = 17.61 = AAA |
| DSRI: 1.38 (Receivables 77.2m/60.0m, Revenue 374.6m/401.6m) |
| GMI: 1.05 (GM 79.98% / 76.52%) |
| AQI: 1.00 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 0.93 (Revenue 374.6m / 401.6m) |
| TATA: -0.02 (NI 77.5m - CFO 88.6m) / TA 720.3m) |
| Beneish M = -2.72 (Cap -4..+1) = A |
As of August 18, 2026, the stock is trading at USD 15.02 with a total of 529,712 shares traded. Over the past week, the price has changed by -1.12%, over one month by -2.91%, over three months by +6.52% and over the past year by +5.00%.
Current recommended Stop Loss: 14.60 (which is 2.8% or 1.5 ATR below the current price).
InMode has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold INMD.
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.3 | 2.1% |
P/E Trailing = 12.4836
P/E Forward = 11.2486
P/S = 2.3394
P/B = 1.3878
P/EG = 2.9004
Revenue TTM = 374.6m USD
EBIT TTM = 83.5m USD
EBITDA TTM = 84.2m USD
Long Term Debt = unknown (none)
Short Term Debt = 3.22m USD (from shortTermDebt, last fiscal year)
Debt = 4.45m USD (from shortLongTermDebtTotal, last quarter) (leases 4.45m already included)
Net Debt = -496.7m USD (calculated: Debt 4.45m - CCE 501.1m)
Enterprise Value = 379.7m USD (876.4m + Debt 4.45m - CCE 501.1m)
Interest Coverage Ratio = unknown (Ebit TTM 83.5m / Interest Expense TTM 0.0)
EV/FCF = 4.34x (Enterprise Value 379.7m / FCF TTM 87.5m)
FCF Yield = 23.03% (FCF TTM 87.5m / Enterprise Value 379.7m)
FCF Margin = 23.34% (FCF TTM 87.5m / Revenue TTM 374.6m)
Net Margin = 20.69% (Net Income TTM 77.5m / Revenue TTM 374.6m)
Gross Margin = 76.52% ((Revenue TTM 374.6m - Cost of Revenue TTM 87.9m) / Revenue TTM)
Gross Margin QoQ = 74.82% (prev 75.05%)
Tobins Q-Ratio = 0.53 (Enterprise Value 379.7m / Total Assets 720.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.45m)
Taxrate = 14.77% (13.4m / 91.0m)
NOPAT = 71.2m (EBIT 83.5m * (1 - 14.77%))
Current Ratio = 8.18 (Total Current Assets 650.0m / Total Current Liabilities 79.4m)
Debt / Equity = 0.01 (Debt 4.45m / totalStockholderEquity, last quarter 629.1m)
Debt / EBITDA = -5.90 (Net Debt -496.7m / EBITDA 84.2m)
Debt / FCF = -5.68 (Net Debt -496.7m / FCF TTM 87.5m)
Total Stockholder Equity = 656.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.85% (Net Income 77.5m / Total Assets 720.3m)
RoE = 11.80% (Net Income TTM 77.5m / Total Stockholder Equity 656.7m)
RoCE = 13.03% (EBIT 83.5m / Capital Employed (Total Assets 720.3m - Current Liab 79.4m))
RoIC = 11.38% (NOPAT 71.2m / Invested Capital 625.4m)
WACC = 8.54% (E(876.4m)/V(880.8m) * Re(8.58%) + D(4.45m)/V(880.8m) * Rd(0.0%) * (1-Tc(0.15)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.24 | Cagr: -15.16%
[DCF] Terminal Value 72.40% ; FCFF base≈94.1m ; Y1≈82.6m ; Y5≈66.7m
[DCF] Fair Price = 26.68 (EV 1.04b - Net Debt -496.7m = Equity 1.54b / Shares 57.5m; r=8.54% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -96.40 | EPS CAGR: -20.54% | SUE: -0.66 | # QB: 0
Revenue Correlation: -92.09 | Revenue CAGR: -10.65% | SUE: 0.29 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.31 | Chg30d=-7.31% | Revisions=-50% | Analysts=3
EPS current Year (2026-12-31): EPS=1.28 | Chg30d=-3.43% | Revisions=-57% | GrowthEPS=-20.2% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=1.41 | Chg30d=-3.16% | Revisions=-25% | GrowthEPS=+10.3% | GrowthRev=+2.4%
[Analyst] Revisions Ratio: -73% (up=0, down=8)